Pfizer is pushing to higher highs.
After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term. All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses. The stock could push even higher on a US CDC vote.
Later today, a US CDC independent advisory panel will vote on recommending the Pfizer vaccine for children aged five to 11.
“If members of the committee vote to recommend use of the vaccine, CDC Director Rochelle Walensky is expected to then issue a recommendation as soon as Tuesday evening, the final step in the process, which would allow the first shots to be administered as soon as Wednesday morning,” as reported by ABC News.
About 15 million doses of the vaccine are expected to be shipped over the net week. Many will be made available at pediatrician offices, children’s hospitals, and vaccination site. About five million doses will be sent to pharmacies across the U.S.
Also, according to Pfizer’s Chairman and CEO, Dr. Albert Bourla, as quoted by TheFly.com:
“While we are proud of our third quarter financial performance, we are even more proud of what these financial results represent in terms of the positive impact we are having on human lives around the world.”
“For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty have come from supplying countries outside the U.S., and we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022 — at least one billion to be delivered this year and one billion next year, with the possibility to increase those deliveries if more orders are placed by these countries for 2022,” he added.
With a good deal of catalysts ahead, Pfizer could see higher highs.